Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
POETIC was an open-label, multicentre, parallel-group, randomized, phase 3 trial done in 130 UK hospitals. Postmenopausal women aged at least 50 years with hormone receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI or no POAI. POAI has not been shown to improve treatment outcome, but can be used without detriment to help select appropriate adjuvant therapy.
